Title | A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Abe, K, Shang, J, Shi, X, Yamashita, T, Hishikawa, N, Takemoto, M, Morihara, R, Nakano, Y, Ohta, Y, Deguchi, K, Ikeda, M, Ikeda, Y, Okamoto, K, Shoji, M, Takatama, M, Kojo, M, Kuroda, T, Ono, K, Kimura, N, Matsubara, E, Osakada, Y, Wakutani, Y, Takao, Y, Higashi, Y, Asada, K, Senga, T, Lee, L-J, Tanaka, K |
Journal | J Alzheimers Dis |
Volume | 73 |
Issue | 1 |
Pagination | 217-227 |
Date Published | 2020 |
ISSN | 1875-8908 |
Abstract | BACKGROUND: Because dementia is an emerging problem in the world, biochemical markers of cerebrospinal fluid (CSF) and radio-isotopic analyses are helpful for diagnosing Alzheimer's disease (AD). Although blood sample is more feasible and plausible than CSF or radiological biomarkers for screening potential AD, measurements of serum amyloid- β (Aβ), plasma tau, and serum antibodies for Aβ1 - 42 are not yet well established. OBJECTIVE: We aimed to identify a new serum biomarker to detect mild cognitive impairment (MCI) and AD in comparison to cognitively healthy control by a new peptidome technology. METHODS: With only 1.5μl of serum, we examined a new target plate "BLOTCHIP®" plus a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) to discriminate control (n = 100), MCI (n = 60), and AD (n = 99). In some subjects, cognitive Mini-Mental State Examination (MMSE) were compared to positron emission tomography (PET) with Pittsburgh compound B (PiB) and the serum probability of dementia (SPD). The mother proteins of candidate serum peptides were examined in autopsied AD brains. RESULTS: Apart from Aβ or tau, the present study discovered a new diagnostic 4-peptides-set biomarker for discriminating control, MCI, and AD with 87% of sensitivity and 65% of specificity between control and AD (***p CONCLUSION: The present serum biomarker set provides a new, rapid, non-invasive, highly quantitative and low-cost clinical application for dementia screening, and also suggests an alternative pathomechanism of AD for neuroinflammation and neurovascular unit damage. |
DOI | 10.3233/JAD-191016 |
Alternate Journal | J Alzheimers Dis |
PubMed ID | 31771070 |
PubMed Central ID | PMC7029318 |